OpenLoop

No telehealth services are confirmed to still safely offer compounded GLP-1s after the FDA’s March and June 2026 crackdowns; major platforms have either stopped offering them entirely or transitioned exclusively to FDA-approved alternatives like Wegovy, Zepbound, and Saxenda [3]. The FDA has issued over 100 warning letters across three enforcement waves (February, March, and June 2026) to telehealth firms for promoting compounded GLP-1s with false or misleading claims, explicitly stating these products lack proven safety, efficacy, or consistent quality [1][2][5]. High-profile companies that previously offered compounded versions have exited the model: Company Status After Crackdown Hims & Hers Exited compounded semaglutide entirely in March 2026; now an authorized distributor of branded Wegovy and Ozempic [3][10] Ro Stopped compounded GLP-1s; now offers Wegovy and Zepbound [3] Good Life Eliminated compounded offerings; focuses on FDA-approved alternatives [3] Medica Weight Loss, Ready Med, Clover Meds Received June 2026 warning letters; compliance status unclear but likely halted or under review [1] Beluga Health, OpenLoop, MD Integrations Affiliations warned; at least 30% of warned companies linked to these groups, suggesting widespread cessation [6] The post-crackdown landscape is shifting to a manufacturer-centric distribution network, where Novo Nordisk and Eli Lilly offer direct-to-telehealth programs bundling FDA-approved drugs with adherence kits and reimbursement interfaces [2]. If you are seeking weight-loss treatment, the safest and most reliable options are currently: Wegovy (Novo Nordisk) – FDA-approved for chronic weight management [3] Zepbound (Eli Lilly) – FDA-approved for weight loss [3] Saxenda (Novo Nordisk) – FDA-approved, often used with generics [3] For access, consult licensed telehealth platforms that now focus on approved medications, such as Ro and Hims & Hers [3]. Compounded GLP-1s remain legally permissible only in rare cases (e.g., specific allergies or unavailable dosages), but mainstream telehealth platforms have largely eliminated them [3][12].

Mentioned in position 8 of 11

Several telehealth brands appear to still offer compounded GLP-1s as of the recent FDA crackdown, but the most important caveat is that the FDA has been issuing warning letters specifically for false or misleading marketing, not announcing a blanket ban on every telehealth compounding arrangement.[2][4][5] Brands mentioned in recent reporting as still in this market include Lovely Meds, Hello Cake, and MEDVi.[4] That same reporting says these companies are among more than 70 telehealth companies warned by the FDA, and that many of them rely on affiliated medical groups such as Beluga Health, OpenLoop, MD Integrations, and Telegra to handle prescribing.[4] A practical way to think about the landscape is: Still active in compounded GLP-1 telehealth: Lovely Meds, Hello Cake, MEDVi[4] Affiliated infrastructure often behind the scenes: Beluga Health, OpenLoop, MD Integrations, Telegra[4] Under FDA scrutiny for marketing claims: telehealth companies broadly, including the 30 firms named in the FDA’s warning-letter action[2] Important nuance: the FDA materials you provided focus on marketing and claims around compounded semaglutide/tirzepatide, not a simple public list of “approved telehealth sellers.”[1][2] Because telehealth availability can change quickly after warning letters, the safest check before buying is whether the service is still taking new GLP-1 patients, which pharmacy it uses, and whether it is offering compounded versus FDA-approved medication.

Mentioned in position 5 of 7